Aurinia Pharmaceuticals (NASDAQ:AUPH) Announces Quarterly Earnings Results

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) issued its quarterly earnings results on Friday. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.01, FiscalAI reports. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%. The business had revenue of $83.70 million for the quarter, compared to the consensus estimate of $83.61 million.

Aurinia Pharmaceuticals Trading Down 3.3%

NASDAQ AUPH opened at $16.65 on Friday. The company has a fifty day simple moving average of $16.49 and a two-hundred day simple moving average of $15.64. The stock has a market cap of $2.22 billion, a P/E ratio of 16.87 and a beta of 1.60. Aurinia Pharmaceuticals has a 12-month low of $12.07 and a 12-month high of $19.25. The company has a current ratio of 5.42, a quick ratio of 4.97 and a debt-to-equity ratio of 0.07.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Royal Bank Of Canada raised their price objective on Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research report on Friday, August 7th. Weiss Ratings raised Aurinia Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 22nd. TD Cowen increased their price target on Aurinia Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, October 21st. Wall Street Zen downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Bloom Burton raised Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 20th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $17.75.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s principal product is Lupkynis (voclosporin), an oral calcineurin inhibitor used in combination with other immunosuppressive therapies to treat adults with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

Voclosporin was approved by the U.S. Food and Drug Administration in 2021, making Lupkynis the first oral therapy specifically approved in the United States for adult patients with active lupus nephritis.